GARCIA RUBEN A 4

What Happened
Ruben A. Garcia, General Counsel of FibroBiologics, was granted an option to purchase 61,607 shares of the company's common stock on May 4, 2026. The Form 4 reports an acquisition type "A" (award/grant) with an acquisition price of $0.00; this is a stock option grant (a derivative), not an open‑market purchase or sale.

Key Details

• Transaction date: May 4, 2026; Form filed on May 4, 2026 (same-day filing).
• Security: Option to purchase 61,607 shares of common stock (derivative).
• Reported acquisition price: $0.00 (typical for option grants on Form 4; strike price or grant value not provided in the filing).
• Vesting: 1/4 of the option vests on the one‑year anniversary of the grant; the remaining shares vest in 36 equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: Not specified in the filing.
• No sale or exercise reported; this is a compensation grant, not a cashless exercise or open‑market trade.

Context
This is a standard equity compensation grant to an executive and does not represent an immediate cash investment or disposition. The option must vest over time and requires continued service to the company. Such grants are common for employee incentives and do not, by themselves, indicate an insider buying or selling shares on the open market.